Європейський Союз - румунська - EMA (European Medicines Agency)

takeda pharma a/s - darvadstrocel - rectala fistula - imunosupresoare - alofisel este indicat pentru tratamentul complex fistule perianale la pacienții adulți cu non-activ/moderat activ luminal boala crohn, când fistule au prezentat un răspuns inadecvat la cel puțin un convenționale sau terapiei biologice. alofisel ar trebui să fie utilizat după condiționat de fistula.

Європейський Союз - румунська - EMA (European Medicines Agency)

shionogi b.v. - naldemedine tosilate - constipație - medicamente pentru constipație, periferice antagoniști ai receptorilor opioizi - rizmoic este indicat pentru tratamentul constipației induse de opioide (oic) la pacienții adulți care au fost tratați anterior cu un laxativ.

Румунія - румунська - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sc deltarom distribution srl -

Румунія - румунська - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sc deltarom distribution srl -

Румунія - румунська - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sc deltarom distribution srl -

Європейський Союз - румунська - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccinuri - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. utilizarea acestui vaccin ar trebui să fie în conformitate cu recomandările oficiale.

Європейський Союз - румунська - EMA (European Medicines Agency)

dynavax gmbh - hepatita b antigen de suprafață - hepatita b - vaccinuri - heplisav b is indicated for the active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes of hepatitis b virus in adults 18 years of age and older. the use of heplisav b should be in accordance with official recommendations. it can be expected that hepatitis d will also be prevented by immunisation with heplisav b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.

Молдова - румунська - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

worwag pharma gmbh & co. kg - gabapentinum - capsule - 300 mg

Румунія - румунська - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sc deltarom srl -

Європейський Союз - румунська - EMA (European Medicines Agency)

vbi vaccines b.v. - hepatita b antigen de suprafață - hepatita b - vaccinuri - prehevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis b virus in adults. it can be expected that hepatitis d will also be prevented by immunisation with prehevbri as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection. the use of prehevbri should be in accordance with official recommendations.